NCT02391961View on ClinicalTrials.gov

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 1, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

March 31, 2019

Conditions
Multiple SclerosisInternuclear OphthalmoplegiaFatigue
Interventions
DRUG

Dalfampridine

10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.

DRUG

Placebo

10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.

Trial Locations (1)

44106

Louis Stokes VA Medical Center, Cleveland, OH, Cleveland

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT02391961 - Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis | Biotech Hunter | Biotech Hunter